2269:HKG
WuXi Biologics (Cayman) Inc
48,20 HK$
arrow_downward
-0,90%(-0,44) 1D
16 okt, 16:08:14 GMT+8 · HKD
search
Bütün simvollar
| Simvol | Qiymət | Dəyişiklik | % Dəyişiklik |
|---|
insights_auto2269 üçün ən vacib statistik məlumatlar yaradılır...
Açın
49,98 HK$
Yüksək
50,85 HK$
Aşağı
45,82 HK$
Bazar kapitalizasiyası
198,43 mlrd
Ortalama həcm
30,42 mln
Həcm
55,18 mln
Qiymət-qazanc nisbəti
34,48
52 həftəlik ən yüksək
58,00 HK$
52 həftəlik ən aşağı
28,48 HK$
EPS
1,40 HK$
Dövriyyədəki səhmlər
1,23 mlrd
İşçilərin sayı
15K
Açın
49,98 HK$
Yüksək
50,85 HK$
Aşağı
45,82 HK$
Bazar kapitalizasiyası
198,43 mlrd
Ortalama həcm
30,42 mln
Həcm
55,18 mln
Qiymət-qazanc nisbəti
34,48
52 həftəlik ən yüksək
58,00 HK$
52 həftəlik ən aşağı
28,48 HK$
EPS
1,40 HK$
Dövriyyədəki səhmlər
1,23 mlrd
İşçilərin sayı
15K
Xəbər materialları
Veb mənbələri və xəbər partnyorlarından
Beinsure
·
7 dəqiqə öncə
Apple (NASDAQ: AAPL) stock forecast: Wall Street analysts split on AAPL’s upside
The Motley Fool
·
1 saat öncə
A Record Number of S&P 500 Companies Issued Upbeat Guidance Before Earnings Season. Should You Buy an Index Fund Now?
Kalkine Media
·
43 dəqiqə öncə
Will Firmus Turn to Nasdaq After Its Failed ASX Float?
Yahoo Finance
·
22 saat öncə
Wall Street’s record breakouts unravel as investors dump recent winners: Chart of the Day
Profil
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
WuXi Biologics (Cayman) Inc haqqında
Baş İcraçı DirektorZhisheng Chen
İşçilər14,7K
Təsis Tarixi2010
Baş Ofis-
SektorHealth care
Veb-saytwuxibiologics.com